Stromal Matrix Metalloproteinase-9 Regulates the Vascular Architecture in Neuroblastoma by Promoting Pericyte Recruitment

Cancer Research

Volumn 64, Issue 5, 2004, Pages 1675-1686

  Chantrain, Christophe F ^a,f   Shimada, Hiroyuki ^b   Jodele, Sonata ^a   Groshen, Susan ^b   Ye, Wei ^b   Shalinsky, David R ^c   Werb, Zena ^d   Coussens, Lisa M ^e   DeClerck, Yves A ^a,g  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c AGOURON PHARMACEUTICALS INC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^g CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; FLUORESCEIN ISOTHIOCYANATE; GELATINASE A; GELATINASE B; LECTIN; MATRIGEL; PRINOMASTAT;

ANGIOGENESIS; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; LIVER METASTASIS; MICROVASCULATURE; MOUSE; NEUROBLASTOMA; NONHUMAN; PERICYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA CELL; SURVIVAL TIME; TUMOR CELL; TUMOR GROWTH; TUMOR VASCULARIZATION; CELL DIVISION; DISEASE COURSE; DRUG ANTAGONISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; VASCULARIZATION;

CELL DIVISION; CELL LINE, TUMOR; DISEASE PROGRESSION; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOVASCULARIZATION, PATHOLOGIC; NEUROBLASTOMA; PERICYTES;

EID: 1642300508     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-0160     Document Type: Article

References (55)

1. Nelson, A. R., Fingleton, B., Rothenberg, M. L., and Matrisian, L. M. Matrix metalloproteinases: biologic activity and clinical implications. J. Clin. Oncol., 18: 1135-1149, 2000.
2. Chang, C., and Werb, Z. The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol., 11: S37-S43, 2001.
3. McCawley, L. J., and Matrisian, L. M. Matrix Metalloproteinases: they're not just for matrix anymore. Curr. Opin. Cell Biol., 13: 534-540, 2001.
4. Stetler Stevenson, W. G., Liotta, L. A., and Kleiner, D. E., Jr. Extracellular matrix: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J., 7: 1434-1441, 1993.
5. Kim, J., Yu, W., Kovalski, K., and Ossowski, L. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell, 94: 353-362, 1998.
6. Himelstein, B. P., Canete Soler, R., Bernhard, E. J., Dilks, D. W., and Muschel, R. J. Metalloproteinases in tumor progression: the contribution of MMP-9. Invasion Metastasis, 14: 246-258, 1994.
7. Coussens, L. M., Tinkle, C. L., Hanahan, D., and Werb, Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell, 103: 481-490, 2000.
8. Basset, P., Okada, A., Chenard, M. P., Kannan, R., Stoll, I., Anglard, P., Bellocq, J. P., and Rio, M. C. Matrix metalloproteinases as stromal effectors of human carcinoma progression: therapeutic implications. Matrix Biol., 15: 535-541, 1997.
9. Himelstein, B. P., and Muschel, R. J. Induction of matrix metalloproteinase 9 expression in breast carcinoma cells by a soluble factor from fibroblasts. Clin. Exp. Metastasis, 14: 197-208, 1996.
10. Guo, H., Zucker, S., Gordon, M. K., Toole, B. P., and Biswas, C. Stimulation of matrix metalloproteinase production by recombinant extracellular matrix metalloproteinase inducer from transfected Chinese hamster ovary cells. J. Biol. Chem., 272: 24-27, 1997.
11. Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., and Hanahan, D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol., 2: 737-744, 2000.
12. Itoh, T., Tanioka, M., Yoshida, H., Yoshioka, T., Nishimoto, H., and Itohara, S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res., 58: 1048-1051, 1998.
13. Chandrasekar, N., Jasti, S., Alfred-Yung, W. K., Ali-Osman, F., Dinh, D. H., Olivero, W. C., Gujrati, M., Kyritsis, A. P., Nicolson, G. L., Rao, J. S., and Mohanam, S. Modulation of endothelial cell morphogenesis in vitro by MMP-9 during glial-endothetial cell interactions. Clin. Exp. Metastasis, 18: 337-342, 2000.
14. Reynolds, C. P., and Seeger, R. C. Neuroblastoma. In: C. Haskell (ed.), Cancer Treatment, Ed. 4, pp. 860-871. Philadelphia: W. B. Saunders, 1994.
15. Matthay, K. K., Villablanca, J. G., Seeger, R. C., Stram, D. O., Harris, R. E., Ramsay, N. K., Swift, P., Shimada, H., Black, C. T., Brodeur, G. M., Gerbing, R. B., and Reynolds, C. P. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N. Engl. J. Med., 341: 1165-1173, 1999.
16. Ara, T., Kusafuka, T., Inoue, M., Kuroda, S., Fukuzawa, M., and Okada, A. Determination of imbalance between MMP-2 and TIMP-2 in human neuroblastoma by reverse-transcription polymerase chain reaction and its correlation with tumor progression. J. Pediatr. Surg., 35: 432-437, 2000.
17. Sugiura, Y., Shimada, H., Seeger, R. C., Laug, W. E., and DeClerck, Y. A. Matrix metalloproteinases-2 and -9 are expressed in human neuroblastoma: contribution of stromal cells to their production and correlation with metastasis. Cancer Res., 58: 2209-2216, 1998.
18. Moats, R., Ma, L. Q., Wajed, R., Sugiura, Y., Lazaryev, A., Tyska, M., Jacobs, R., Fraser, S. E., Nelson, M. D., Jr., and DeClerck. Y. A. Magnetic resonance imaging for the evaluation of a novel metastatic orthotopic model of human neuroblastoma in immunodeficient mice. Clin. Exp., Metastasis, 18: 455-461, 2001.
19. Vu, T. H., Shipley, J. M., Bergers, G., Berger, J. E., Helms, J. A., Hanahan, D., Shapiro, S. D., Senior, R. M., and Werb, Z. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell, 93: 411-422, 1998.
20. Chen, J., Shinkai, Y., Young, F., and Alt, F. W. Probing immune functions in RAG-deficient mice. Curr. Opin. Immunol., 6: 313-319, 1994.
21. Chantrain, C. F., De Clerck, Y. A., Groshen, S., and McNamara, G. Computerized quantification of tissue vascularization using high resolution slide scanning of whole tumor sections. J. Histochem. Cytochem., 51: 151-158, 2003.
22. Wirnsberger, G. H., Becker, H., Ziervogel, K., and Hofler, H. Diagnostic immunohistochemistry of neuroblastic tumors. Am. J. Surg. Pathol., 16: 49-57, 1992.
23. Shalinsky, D. R., Brekken, J., Zou, H., Kolis, S., Wood, A., Webber, S., and Appelt, K. Antitumor efficacy of AG3340 associated with maintenance of minimum effective plasma concentrations and not total daily dose, exposure or peak plasma concentrations. Investig. New Drugs, 16: 303-313, 1998.
24. Huang, S., Van Arsdall, M., Tedjarati, S., McCarty, M., Wu, W., Langley, R., and Fidler, I. J. Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J. Natl. Cancer Inst. (Bethesda), 94: 1134-1142, 2002.
25. Shalinsky, D. R., Brekken, J., Zou, H., Bloom, L. A., McDermott, C. D., Zook, S., Varki, N. M., and Appelt, K. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies. Clin. Cancer Res., 5: 1905-1917, 1999.
26. Shalinsky, D. R., Brekken, J., Zou, H., McDermott, C. D., Forsyth, P., Edwards, D., Margosiak, S., Bender, S., Truitt, G., Wood, A., Varki, N. M., and Appelt, K. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann. N. Y. Acad. Sci., 878: 236-270, 1999.
27. Price, A., Shi, Q., Morris, D., Wilcox, M. E., Brasher, P. M., Rewcastle, N. B., Shalinsky, D., Zou, H., Appelt, K., Johnston, R. N., Yong, V. W., Edwards, D., and Forsyth, P. Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340. Clin. Cancer Res., 5: 845-854, 1999.
28. Kleiner, D. E., and Stetler-Stevenson, W. G. Matrix metalloproteinases and metastasis. Cancer Chemother. Pharmacol., 43: S42-S51, 1999.
29. Coussens, L. M., Fingleton, B., and Matrisian, L. M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science (Wash. DC), 295: 2387-2392, 2002.
30. Tsunezuka, Y., Kinoh, H., Takino, T., Watanabe, Y., Okada, Y., Shinagawa, A., Sato, H., and Seiki, M. Expression of membrane-type matrix metalloproteinase 1 (MT1-MMP) in tumor cells enhances pulmonary metastasis in an experimental metastasis assay. Cancer Res., 56: 5678-5683, 1996.
31. Noel, A., Lefebvre, O., Maquoi, E., VanHoorde, L., Chenard, M. P., Mareel, M., and Foidart, J. M. Stromelysin-3 expression promotes tumor take in nude mice. J. Clin. Investig., 97: 1924-1930, 1996.
32. Khokha, R. Suppression of the tumorigenic and metastatic abilities of murine B 16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinases-1. J. Natl. Cancer Inst. (Bethesda), 86: 299-304, 1994.
33. Hua, J., and Muschel, R. J. Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res., 56: 5279-5284, 1996.
34. Alvarez, O. A., Carmichael, D. F., and DeClerck, Y. A. Inhibition of collagenolytic activity and metastasis of tumor cells by a recombinant human tissue inhibitor of metalloproteinases. J. Natl. Cancer Inst. (Bethesda), 82: 589-595, 1990.
35. Khokha, R., Zimmer, M. J., Wilson, S. M., and Chambers, A. F. Up-regulation of TIMP-1 expression in B16-F10 melanoma cells suppresses their metastatic ability in chick embryo. Clin. Exp. Metastasis, 10: 365-370, 1992.
36. Eccles, S. A., Box, G. M., Court, W. J., Bone, E. A., Thomas, W., and Brown, P. D. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res., 56: 2815-2822, 1996.
37. Koop, S., Khokha, R., Schmidt, E. E., MacDonald, I. C., Morris. V. L., Chambers, A. F., and Groom, A. C. Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth. Cancer Res., 54: 4791-4797, 1994.
38. Chambers, A. F., MacDonald, I. C., Schmidt, E. E., Morris, V. L., and Groom, A. C. Preclinical assessment of anti-cancer therapeutic strategies using in vivo videomicroscopy. Cancer Metastasis Rev., 17: 263-269, 1998.
39. Montgomery, A. M., Mueller, B. M., Reisfeld, R. A., Taylor, S. M., and DeClerck, Y. A. Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line. Cancer Res., 54: 5467-5473, 1994.
40. van Kempen, L. C., and Coussens, L. M. MMP9 potentiates pulmonary metastasis formation. Cancer Cell, 2: 251-252, 2002.
41. Al Mehdi, A. B., Tozawa, K., Fisher, A. B., Shientag, L., Lee, A., and Muschel, R. J. Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nat. Med., 6: 100-102, 2000.
42. Wong, C. W., Song, C., Grimes, M. M., Fu, W., Dewhirst, M. W., Muschel, R. J., and Al Mehdi, A. B. Intravascular location of breast cancer cells after spontaneous metastasis to the lung. Am. J. Pathol., 161: 749-753, 2002.
43. Hiratsuka, S., Nakamura, K., Iwai, S., Murakami, M., Itoh, T., Kijima, H., Shipley, J. M., Senior, R. M., and Shibuya, M. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell, 2: 289-300, 2002.
44. Park, M. J., Park, I. C., Lee, H. C., Woo, S. H., Lee, J. Y., Hong, Y. J., Rhee, C. H., Lee, Y. S., Lee, S. H., Shim, B. S., Kuroki, T., and Hong, S. I. Protein kinase C α activation by phorbol ester induces secretion of gelatinase B/MMP-9 through ERK 1/2 pathway in capillary endothelial cells. Int. J. Oncol., 22: 137-143, 2003.
45. Qian, X., Wang, T. N., Rothman, V. L., Nicosia, R. F., and Tuszynski, G. P. Thrombospondin-1 modulates angiogenesis in vitro by up-regulation of matrix metalloproteinase-9 in endothelial cells. Exp. Cell Res., 235: 403-412, 1997.
46. Pozzi, A., LeVine, W. F., and Gardner, H. A. Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis. Oncogene, 21: 272-281, 2002.
47. Maeshima, Y., Sudhakar, A., Lively, J. C., Ueki, K., Kharbanda, S., Kahn, C. R., Sonenberg, N., Hynes, R. O., and Kalluri, R. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science (Wash. DC), 295: 140-143, 2002.
48. Carmeliet, P. Mechanisms of angiogenesis and arteriogenesis. Nat. Med., 6: 389-395, 2000.
49. Gerhardt, H., and Betsholtz, C. Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res., 314: 15-23, 2003.
50. Hellstrom, M., Gerhardt, H., Kalen, M., Li, X., Eriksson, U., Wolburg, H., and Betsholtz, C. Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J. Cell Biol., 153: 543-553, 2001.
51. Carmeliet, P. Angiogenesis in health and disease. Nat. Med., 9: 653-660, 2003.
52. Hellstrom, M., Kalen, M., Lindahl, P., Abramsson, A., and Betsholtz, C. Role of PDGF-B and PDGFR-β in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development (Camb.), 126: 3047-3055, 1999.
53. Spurbeck, W. W., Ng, C. Y., Strom, T. S., Vanin, E. F., and Davidoff, A. M. Enforced expression of tissue inhibitor of matrix metalloproteinase-3 affects functional capillary morphogenesis and inhibits tumor growth in a murine tumor model. Blood, 100: 3361-3368, 2002.
54. Forsyth, P. A., Wong, H., Laing, T. D., Rewcastle. N. B., Morris, D. G., Muzik, H., Leco, K. J., Johnston, R. N., Brasher, P. M. A., Sutherland, G., and Edwards, D. R. Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br. J. Cancer, 79: 1828-1835, 1999.
55. Arihiro, S., Ohtani, H., Hiwatashi, N., Torii, A., Sorsa, T., and Nagura, H. Vascular smooth muscle cells and pericytes express MMP-1, MMP-9, TIMP-1 and type I procollagen in inflammatory bowel disease. Histopathology, 39: 50-59, 2001.